DocWire News Editors

DocwireNews

A prospective, randomized clinical trial compared two different treat-and-extend protocols with aflibercept in wet age-related macular degeneration (AMD).A total of 52 treatment-na&iuml;ve eyes (52 patients) with wet AMD underwent an induction phase of three monthly aflibercept injections, after which they were randomized 1:1 to one of the treat-and-extend protocols. The treat-and-extend protocol with moderate extensions (T&amp;Em) extended the treatment interval one week at a time up to 12 weeks and then by two weeks up to 16 weeks. The treat-and-extended protocol with rapid extensions (T&amp;Er) initially extended the treatment interval to eight weeks and then by two weeks up to 16 weeks. The primary outcome was the number of given aflibercept injections.After two years, the mean visual gain from the baseline was 7.9&thinsp;&plusmn;&thinsp;14.5 letters in the T&amp;Em group and 10.8&thinsp;&plusmn;&thinsp;16.5 letters in the T&amp;Er group. The central subfield macular thickness decreased by a mean 203.0&thinsp;&plusmn;&thinsp;167.4 &micro;m in the T&amp;Em group and 192.3&thinsp;&plusmn;&thinsp;160.2 &micro;m in the T&amp;Er group. At the end of year two, the treatment interval was 10.3&thinsp;&plusmn;&thinsp;3.3 weeks in the T&amp;Em group and 11.7&thinsp;&plusmn;&thinsp;3.5 in the T&amp;Er group. Over two years, the total number of injections was 14.1&thinsp;&plusmn;&thinsp;3.1 in the T&amp;Em group and 11.6&thinsp;&plusmn;&thinsp;2.0 in the T&amp;Er group; during the second year, the total number of injections was 5.4&thinsp;&plusmn;&thinsp;1.8 in the T&amp;Em group and 4.4&thinsp;&plusmn;&thinsp;1.4 in the T&amp;Er group. In both groups, 71% of eyes had a dry macula at two years.&ldquo;At two years, the anatomical and functional responses between the two treatment groups were similar. However, the number of given aflibercept injections was smaller in the [T&amp;Er] protocol,&rdquo; the researchers summarized.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Aflibercept in Wet AMD: Two Treat-and-Extend Protocols

Ophthalmology

A prospective, randomized clinical trial compared two different treat-and-extend protocols with aflibercept in wet age-related macular degeneration (AMD). ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe